{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"HealthTech Remedy","title":"Pharmacist to Venture Capitalist: On Startups & Leadership with Meg Powell","html":"","width":"100%","height":180,"duration":2636,"description":"How does a pharmacist become a venture capitalist? Hear Meg Powell's story on the transition from big pharma to startup and her advice for women in healthcare leadership.Episode resources:Learn about 501 VenturesFollow Meg Powell on LinkedInHave you ever wondered if your clinical training could lead to a career in high-stakes investing? This episode charts the incredible journey of Meg Powell, who forged a unique path from pharmacist to venture capitalist. Meg shares the invaluable lessons, pivotal moments, and scrappy determination that took her from a small town in North Carolina to the executive suites of Big Pharma, the trenches of a successful startup, and finally to the helm of her own venture capital firm. We explore the core question: How do you build a multifaceted career in healthcare, and what does it truly take to transition from clinician to entrepreneur to investor?In this deep-dive conversation, Meg Powell, co-founder and CEO of 501 Ventures, reveals the playbook for navigating a dynamic career in the life sciences. She details her foundational years at Eli Lilly and GSK, explaining why a transition from big pharma to startup life provided her with indispensable training and an unparalleled network. Meg walks us through the origin story of Target RWE, a pioneering real world evidence company she co-founded with Dr. Mike Freed. She shares the challenges of building a profitable company from the ground up with minimal funding, the importance of finding the right co-founder, and the strategy behind their successful exit. We also learn about her experience with imposter syndrome and how being a \"scrappy entrepreneur\" became her greatest asset.Now, Meg is focused on the next frontier of medicine through healthcare venture capital. She discusses the formation of 501 Ventures with her partner Enrique Conterno (former President of Lilly Diabetes) and their investment thesis in the booming metabolic health and obesity market, fueled by innovations like...","thumbnail_url":"https://img.transistorcdn.com/Al9s4QJpRCg2VJ2YaV_fo3tDCayXbUO7NTDbnFeSAUQ/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mNTVk/OTAwMzQxYWFiZmYy/ZWFlNzFmN2RmOTcx/MDMwNy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}